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Abstract 
Background: Liver-gallbladder dampness-heat (LGDH) and liver kidney yin deficiency (LKYD) syndromes are Chinese 
medicine (CM) zhengs in chronic hepatitis B (CHB) patients. This study aims to investigate the changes in cytokines 
and their profiles accompanied by different biological responses in LGDH and LKYD in CHB.
Methods: During 2010–2012, a total of 138 morning fasting venous blood samples were obtained from participants 
in Shuguang Hospital, Shanghai University of Traditional Chinese Medicine in Shanghai, China. First, serum sam‑
ples from 20 health controls (HCs) and 40 CHB patients (20 LGDH, 20 LKYD) were collected to detect the profiles of 
cytokines by multiplex biometric ELISA‑based immunoassay. Random forest (RF) with a fivefold cross‑validation was 
used to analyze the significant cytokines. Then the significant cytokines were validated using serum samples from an 
independent cohort of 60 CHB patients (30 LGDH, 30 LKYD) and 18 HCs.
Results: There were different profiles of cytokines in LGDH and LKYD. Twenty‑three significantly differentially 
expressed cytokines were detected, among which three cytokines, interleukin (IL)‑17, macrophage inflammatory pro‑
tein (MIP)‑1α, and MIP‑1β, with the largest Gini scores were identified by RF, and further evaluated for their significant 
changes in serum levels. A receiver‑operator characteristic analysis revealed that the logistic regression panel could 
differentiate LGDH from LKYD (P < 0.001; AUC = 0.827). A functional pathway analysis showed that cytokine–cytokine 
receptor interaction, cytosolic DNA‑sensing pathway, and chemokine signaling pathway overlapped between LGDH 
and LKYD, whereas Toll‑like receptor signaling pathway, intestinal immune network for IgA production, NOD‑like 
receptor signaling pathway, and Jak‑STAT signaling pathway were only enriched in LGDH.
Conclusions: There were characteristic cytokines profiles in LGDH and LKYD with different inflammatory and 
immune responses. IL‑17, MIP‑1α, and MIP‑1β might be involved in the differentiation of LGDH and LKYD in CHB.
© 2015 Lu et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hepatitis B virus (HBV) infection is a potentially adverse 
sequela of chronic liver failure [1]. Recent epidemiologi-
cal studies and the World Health Organization estimated 
that more than 240 million people have chronic (long-
term) liver infections globally [2]. More than 780,000 
people die every year from the acute or chronic conse-
quences of hepatitis B [3]. Moreover, chronic hepatitis B 
(CHB) increases the risk for development of cirrhosis and 
hepatocellular carcinoma [1, 4].
Chinese medicine (CM) has been used for the treat-
ment of liver disease in Asia [5]. Zheng (also known as 
CM syndrome) in CM theory discerns the patterns of 
imbalances within the body and between the body and 
the environment through analysis of the symptoms and 
signs of patients. Zheng differentiation by clinical obser-
vations and CM practitioners’ experiences, are subjective. 
Clarifying the biological basis of CM zheng differentia-
tion would help establish the objective diagnostic criteria 
for CM [6].
Clinical pathological changes are referred to CM 
zhengs. A zheng is not merely a phenotype based on the 
profile of symptoms and signs, but reflects a functional 
dynamic process that can “transform” from one cat-
egory to another. A zheng evolves over time with liver 
damage in CHB. The excess syndrome tends to become 
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a deficiency syndrome or intermingled deficiency and 
excess syndromes. At the same time, with the develop-
ment of the disease, cytokines, chemokines, and growth 
factors secreted by immune system cells and other cell 
types play important roles in viral clearance, infection 
control, inflammation, regeneration, and fibrosis in CHB 
[7]. However, the relationships between typical zhengs 
and cytokines remain unclear.
Reductionist approaches are not suitable for research 
on the scientific basis of CM [8, 9]. In recent years, there 
has been great interest in searches for possible biomark-
ers of zhengs by high-throughput omic technologies [10]. 
High-throughput techniques allow simultaneous exami-
nation of dozens or hundreds of proteins and analytical 
tools facilitate information extraction.
Changes in cytokines were reported to be objec-
tive indicators of CM zhengs [11]. Liver-gallbladder 
dampness-heat (LGDH) and liver kidney yin deficiency 
(LKYD) syndromes are the two major zhengs in CHB 
[4]. They are typical zhengs representing the excess syn-
drome and deficiency syndrome, respectively. This study 
aims to investigate the changes in cytokines and their 
profiles accompanied by different biological responses 
in LGDH and LKYD in CHB. We investigated the 
cytokine profiles in LGDH and LKYD, and the differen-
tial expressions of cytokines as potential markers and 
different biological responses for zheng differentiation 
in CHB (Fig. 1).
Methods
Participant recruitment and sample collection
During 2010–2012, a total of 138 morning fasting venous 
blood samples were obtained from participants in Shu-
guang Hospital, Shanghai University of Traditional Chi-
nese Medicine in Shanghai, China. Healthy volunteers 
were recruited in the Physical Examination Center of 
the Shuguang hospital. First, serum samples from 20 
health controls (HCs) and 40 CHB patients (20 LGDH, 20 
LKYD) were collected to detect the profiles of cytokines 
by multiplex biometric ELISA-based immunoassay. Then 
the significant cytokines were validated using serum 
samples from an independent cohort of 60 CHB patients 
(30 LGDH, 30 LKYD) and 18 HCs. The research proto-
col was approved by the Medical Ethics Committee of 
Shuguang Hospital (Approval number: 2012-206-22-
02; Additional file 1), and informed consent (Additional 
file 2) was obtained from all study participants. The diag-
nostic criteria for CHB were based on CHB prevention 
and treatment guidelines [6]. The zheng types were iden-
tified according to the guideline for the prevention and 
treatment of CHB, formulated by the Chinese Society of 
Hepatology and Chinese Society of Infectious Diseases, 
Chinese Medical Association (pilot program) [12]. All 
patients who were diagnosed by attending CM physi-
cians at the first visit and then identified by three chief 
CM physicians, who generally are the superior of other 
physicians and usually have over 30 years practice in CM. 
Fig. 1 Flow diagram of the study.
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Those participants who consistently diagnosed as LGDH 
or LKYD by all three chief CM physicians, were included 
in the study. Participants with a different diagnosis of any 
one of the three chief CM physicians were excluded. 
Patients with other hepatotropic virus hepatitis, chronic 
severe hepatitis, serious primary disease, or pregnancy 
were excluded.
Clinical parameter assessments
Clinical data including age and sex were recorded by a 
senior physician. Serum levels of total bilirubin (TBIL), 
direct bilirubin (DBIL), indirect bilirubin (IDBIL), ala-
nine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), gamma glutamyl transferase (GGT), 
alkaline phosphatase (ALP), total protein (TP), albu-
min (ALB), total bile acid (TBA), Hepatitis B  Surface 
Antigen (HBsAg), Hepatitis B e antigen (HBeAg), and 
HBV-DNA were measured by an automatic biochemi-
cal analyzer (Model LX-20; Beckman, Fullerton, USA). 
HBsAg, HBeAg, and HBV-DNA were additionally ana-
lyzed by an Architect i2000 system (Abbott Laboratories, 
Abbott Park, IL, USA).
Multiplex biometric ELISA‑based immunoassay using the 
BioPlex assay and Millipore xMAP assay
Serum samples were collected by centrifugation (Model 
3500; KUBOTA, Tokyo, Japan) at 5,700×g for 10 min at 
4  °C, aliquoted, and stored at −80  °C until analysis. A 
multiplex biometric ELISA-based immunoassay, contain-
ing dyed microspheres conjugated with a monoclonal 
antibody specific for a target protein, was used accord-
ing to the manufacturer’s instructions. Soluble molecules 
were measured using two commercially available kits 
(BioPlex Assay:  M50-0  KCAF0Y, MF0-005KMII; Bio-
Plex, Bio-Rad Laboratories Inc., Hercules, CA, USA): (1) 
27-Plex panel, including IL-1β, IL-1rα, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, 
Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-
1, MIP-1α, MIP-1β, PDGF-ββ, RANTES, TNF-α, and 
VEGF; and (2) 21-Plex panel including IL-1α, IL-2Rα, 
IL-3, IL-12p40, IL-16, IL-18, CTACK, GROα, CXCL9, 
SDF-1α, HGF, IFNα2, LIF, MCP-3, M-CSF, MIF, β-NGF, 
SCF, SCGF-β, TNF-β, and TRAIL.
A Millipore xMAP Kit (HCYTOMAG-60K-06; Merck 
Millipore, Billerica, MA, USA) was applied to detect the 
serum levels of IL-17, MIP-1α, and MIP-1β in another 
independent cohort of patients for validation.
Each experiment was performed in duplicate by 
the same procedure. The serum levels of cytokines 
were determined by a suspension array (Luminex 200; 
Luminex, Austin, TX, USA) that quantifies multiplex 
immunoassays in a 96-well plate with 30-μL aliquots 
of serum samples. The cytokine concentrations were 
calculated using a standard curve, with the software pro-
vided by the manufacturer.
Random forest (RF)
RF uses an ensemble of classification trees [13], and 
returns small sets of independent variables that retain 
a high predictive accuracy. In this study, we used RF to 
rank the contribution of each cytokine to discriminate 
between outcomes of patients with different typical 
zhengs, as a possible index for their biological contribu-
tions to the discrimination. The RF method was con-
ducted using the “Random Forest” package [14] with R 
software (R Foundation for Statistical Computing, ver-
sion 3.0). A fivefold cross-validation for feature selection 
of RF was conducted by the “regularized random forest 
(RRF)” package [15, 16].
Each of the classification trees was built using a boot-
strap sample of the data. At each split, the candidate set 
of variables was a random subset of the total variables. 
Thus, RF used both bagging (bootstrap aggregation), a 
successful approach to combining unstable learners, and 
random variable selection for tree building [17]. Each 
tree was grown using the classification and regression 
tree (CART) methodology without pruning. The CART 
is an iterative classification method for variable selec-
tion and prediction of categorical response variables that 
uses a splitting rule to identify a predictive variable and a 
cutoff that best breaks the population into homogenous 
classes. The seed for the random number generator was 
set to ensure repeatability. In this study, the seed was set 
at 51. The number of input variables tried for each node 
was the square root of the number of total variables, and 
the minimum size of the terminal nodes was set at 2.
Statistical analysis and functional pathway analysis
All tests for significance were two-sided. Statistical analy-
ses were conducted and false discovery rate-adjusted P 
values were used for multiple comparisons. To compare 
variables between two groups, the Mann–Whitney U 
test was applied. To compare variables among multiple 
groups, the Kruskal–Wallis analysis of variance by ranks 
test was performed. A stepwise logistic regression model 
was used to combine diagnostic cytokine markers based 
on the data obtained in the validation group. The pre-
dicted probability of differentiating LGDH from LKYD 
was used as a surrogate marker to construct a receiver-
operating characteristic (ROC) curve. The area under 
the ROC curve (AUC) was used as an accuracy index 
for evaluating the diagnostic performance. All tests were 
two-tailed and P values of less than 0.05 were considered 
statistically significant. A functional pathway analysis was 
performed using the DAVID online analysis tool (http://
www.david.abcc.ncifcrf.gov).
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Results
Characteristics of the participants
A total of 100 CHB patients (50 LGDH, 50 LKYD) and 38 
healthy controls (HCs) were finally enrolled in the study. 
Forty patients (20 LGDH, 20 LKYD) and 20 HCs were 
enrolled in the test phase, and 60 patients (30 LGDH, 30 
LKYD) and 18 HCs were enrolled in the validation phase 
(Table  1). The CHB patients were diagnosed as typical 
LGDH and LKYD and the HC group was derived from 
healthy volunteers.
The clinical parameters of the patients and HCs 
enrolled in this study based on the western medical diag-
nostic approach are shown in Table  1. Compared with 
the HCs, the levels of ALT, AST, GGT, ALP, TP, and 
TBA were significantly increased (P < 0.01) in the CHB 
patients. However, the clinical parameters of LGDH and 
LKYD showed no difference (P  >  0.05). These param-
eters could differentiate the CHB patients from the HCs, 
but were unsuitable for the classification of LGDH and 
LKYD.
Comparisons of cytokine levels
The comparisons of the cytokine levels are summarized 
in Table  2. Among the total of 48 cytokines, the serum 
concentrations of IL-2, IL-15, Eotaxin, G-CSF, RANTES, 
GROα, IL-1α, IL-3, IL-12p40, MCP-3, M-CSF, SDF-1α, 
and TNF-β were beyond the detection range in both 
groups, and these cytokines were excluded from fur-
ther analyses. The serum levels of nine cytokines, IL-1β, 
IL-12, IL-17, FGF basic, IFN-γ, MIP-1α, MIP-1β, TNF-
α, and IFN-α2, were significantly differentially expressed 
between the LGDH group and the LKYD group 
(P < 0.05). Meanwhile, the serum levels of 16 cytokines, 
IL-1β, IL-8, IL-17, FGF basic, GM-CSF, IFN-γ, IP-10, 
MIP-1α, PDGF-ββ, VEGF, CTACK, IL-18, LIF, MIG, SCF, 
and SCGF-β, were significantly differentially expressed 
for multiple comparisons of the LGDH, LKYD, and HC 
groups (P < 0.05). Two patches of 23 significantly differ-
entially expressed cytokines were merged for subsequent 
analysis.
LGDH and LKYD classification and candidate cytokine 
discovery
Twenty-three cytokines were analyzed by RF in the 
LGDH, LKYD, and HC groups. The results showed a 
high classification accuracy between the LGDH and 
LKYD groups (Fig. 2a). The contributions of the individ-
ual cytokines for classifying LGDH and LKYD were also 
calculated. IL-17, MIP-1α, and MIP-1β were found to be 
required for maximum classification accuracy with first 
three Gini scores. (Fig. 2b). With 5-fold cross validation 
(CV) of RF, the model was optimized by selecting the 
least promising variable with the least CV error. The CV 
error reached the lowest when the number of variables 
were two (Additional file  3). Combining both the Gini 
score and the CV error, we chose three cytokines IL-17, 
MIP-1α, and MIP-1β for subsequent validation.
Validation of IL‑17, MIP‑1α, and MIP‑1β selected by RF
Following the computational analyses of RF, an ELISA-
based immunoassay was performed on a cohort of inde-
pendent samples from LGDH patients (n = 30), LKYD 
Table 1 Clinical characteristics of the CHB and HC groups
Significant P values are in italics (P < 0.05)
Symbol "–": Health Control group do not have the data of HBsAg, HBeAg and Log HBV-DNA.
Parameters LGDH LKYD HC P value (LGDH/LKYD) P value (CHB/HC)
Age (years) 35.3 ± 14.2 36.5 ± 12.2 35.1 ± 18.4 0.654 0.809
Gender (M/F) 18/2 19/1 11/9 0.307 0.432
TBIL (μmol/L) 17.0 ± 7.8 18.1 ± 6.5 15.2 ± 3.6 0.403 0.485
DBIL (μmol/L) 5.3 ± 2.6 4.8 ± 2.0 4.3 ± 0.6 0.650 0.502
IDBIL (μmol/L) 10.9 ± 4.9 13.2 ± 5.3 10.9 ± 3.3 0.131 0.401
ALT (IU/L) 60.9 ± 66.5 66.2 ± 70.8 18.3 ± 6.9 0.721 0.000
AST (IU/L) 48.6 ± 32.3 57.4 ± 49.9 18.6 ± 6.0 0.795 0.000
GGT (IU/L) 37.8 ± 22.6 33.8 ± 17.4 17.4 ± 6.2 0.506 0.000
ALP (IU/L) 95.4 ± 37.7 85.3 ± 25.7 61.2 ± 15.9 0.417 0.000
TP (g/L) 75.4 ± 7.1 79.1 ± 5.1 69.5 ± 7.0 0.470 0.000
ALB (g/L) 45.0 ± 3.8 46.0 ± 2.9 43.3 ± 3.9 0.548 0.054
TBA (μmol/L) 15.8 ± 24.7 9.4 ± 16.5 8.3 ± 1.9 0.295 0.006
HBsAg (IU/mL) 236.9 ± 50.0 236.8 ± 57.4 – 0.780 –
HBeAg (S/CO) 189.7 ± 354.2 422.2 ± 562.3 – 0.380 –
Log HBV‑DNA (copies/mL) 6.7 ± 7.3 6.9 ± 7.3 – 0.882 –
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Table 2 Comparisons of cytokine levels (pg/mL) by the BioPlex assay (mean ± SD)
Cytokines LGDH (n = 20) LKYD (n = 20) HC (n = 20) P value of (LGDH/LKYD) P value of (CHB/HC)
Group I
 IL‑1β 2.5 ± 1.5 3.5 ± 1.5 3.4 ± 1.5 0.011 0.016
 IL‑1rα 176.9 ± 129.7 246.3 ± 168.1 201.8 ± 159.8 0.065 0.188
 IL‑2 BDR BDR BDR BDR –
 IL‑4 3.1 ± 2.1 3.5 ± 2.0 3.9 ± 2.4 0.101 0.096
 IL‑5 3.9 ± 1.9 5.0 ± 1.7 4.4 ± 2.1 0.127 0.302
 IL‑6 9.9 ± 7.6 10.7 ± 8.2 8.2 ± 4.8 0.365 0.578
 IL‑7 15.6 ± 7.2 15.8 ± 5.9 16.0 ± 7.4 0.089 0.226
 IL‑8 30.5 ± 18.4 27.1 ± 13.2 48.8 ± 57.4 0.134 0.042
 IL‑9 62.8 ± 103.6 41.1 ± 83.3 8.3 ± 6.8 0.444 0.323
 IL‑10 10.6 ± 11.7 28.6 ± 92.7 8.8 ± 2.7 0.235 0.340
 IL‑12 (p70) 21.5 ± 24.8 30.2 ± 50.9 18.6 ± 9.5 0.035 0.095
 IL‑13 12.8 ± 8.1 14.5 ± 7.2 13.1 ± 5.8 0.113 0.208
 IL‑15 BDR BDR BDR – –
 IL‑17 1.6 ± 2.9 4.8 ± 4.5 4.4 ± 3.9 0.006 0.007
 Eotaxin BDR BDR BDR – –
 FGF basic 17.8 ± 12.8 22.3 ± 12.0 19.7 ± 9.3 0.019 0.040
 G‑CSF BDR BDR BDR – –
 GM‑CSF 29.5 ± 32.9 29.0 ± 30.1 71.0 ± 35.2 0.107 0.003
 IFN‑γ 133.4 ± 90.2 150.3 ± 86.8 141.1 ± 108.2 0.033 0.086
 IP‑10 820.7 ± 665.7 1,076.9 ± 733.4 408.9 ± 394.7 0.478 0.000
 MCP‑1 (MCAF) 76.8 ± 46.2 70.3 ± 42.8 67.1 ± 35.4 0.496 0.755
 MIP‑1α 5.3 ± 2.2 3.6 ± 2.0 5.2 ± 2.4 0.004 0.005
 MIP‑1β 154.5 ± 70.4 230.9 ± 101.5 196.3 ± 149.5 0.026 0.064
 PDGF‑ββ 6,536.6 ± 977.7 11,116.8 ± 1,731.4 ADR 0.054 0.008
 RANTES ADR ADR ADR – –
 TNF‑α 27.7 ± 21.5 26.7 ± 12.9 23.9 ± 12.1 0.026 0.110
 VEGF 115.7 ± 93.6 90.9 ± 53.1 158.6 ± 82.6 0.749 0.016
Group II
 CTACK 1063.6 ± 399.7 1059.6 ± 574.4 606.9 ± 269.0 0.728 0.002
 GROα BDR BDR BDR – –
 HGF 940.1 ± 369.3 973.0 ± 424.8 776.9 ± 248.1 0.945 0.375
 IFN‑α2 145.7 ± 55.0 187.1 ± 49.2 181.9 ± 60.0 0.047 0.108
 IL‑1α BDR BDR BDR – –
 IL‑2Rα 411.0 ± 297.1 414.6 ± 451.6 435.1 ± 431.0 0.945 0.565
 IL‑3 BDR BDR BDR – –
 IL‑12p40 BDR BDR BDR – –
 IL‑16 933.7 ± 784.2 968.0 ± 794.5 525.8 ± 335.6 0.627 0.146
 IL‑18 235.3 ± 99.6 309.7 ± 204.9 166.1 ± 90.1 0.513 0.022
 LIF 13.2 ± 16.2 15.6 ± 13.2 21.8 ± 12.2 0.089 0.046
 MCP‑3 BDR BDR BDR – –
 M‑CSF BDR BDR BDR – –
 MIF 679.2 ± 548.0 578.1 ± 422.1 587.3 ± 370.4 0.901 0.961
 MIG 1,255.3 ± 995.3 1,793.4 ± 1,382.2 900.4 ± 837.2 0.101 0.044
 β‑NGF 2.6 ± 2.3 3.1 ± 2.1 4.8 ± 1.9 0.158 0.085
 SCF 215.9 ± 83.7 219.2 ± 82.9 143.7 ± 41.5 0.336 0.008
 SCGF‑β 87,492.2 ± 33,886.1 90,081.1 ± 24,518.4 51,470.7 ± 14,275.2 0.065 0.002
 SDF‑1α BDR BDR BDR – –
 TNF‑β BDR BDR BDR – –
 TRAIL 209.5 ± 183.4 200.3 ± 143.4 213.0 ± 89.4 0.478 0.443
Significant P values are in italics (P < 0.05)
BDR below the detection range and ADR above the detection range. Symbol “–”: Serum concentrations of IL-2, IL-15, Eotaxin, G-CSF, RANTES, GROα, IL-1α, IL-3, 
IL-12p40, MCP-3, M-CSF, SDF-1α, and TNF-β were beyond the detection range in both groups, thus there were no significant test result of these cytokines.
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patients (n  =  30), and HCs (n  =  18). The expression 
results for IL-17, MIP-1α, and MIP-1β were consist-
ent with the results from the multiplex assay. We found 
statistical significance for these three cytokines (Fig. 3). 
The IL-17 levels were elevated significantly (P  =  0.02) 
in the LKYD group compared with the LGDH group. 
The MIP-1α levels (P  =  0.004) were decreased in the 
LKYD group compared with the LGDH group, while 
the LGDH and LKYD groups were both remarkably 
different from the HC group. The MIP-1β (P =  0.006) 
expression levels of LKYDS were significantly differ-
ent compared with the HC group (Fig.  3). There was 
no significant difference between the LGDH and LKYD 
groups (P = 0.081).
Sensitivity and specificity of IL‑17, MIP‑1α, and MIP‑1β 
for LGDH and LKYD differentiation
The levels of IL-17, MIP-1α, and MIP-1β expressions in 
LGDH and LKYD were compared. As shown in Fig.  4, 
the AUC values for IL-17, MIP-1α were 0.663 (P = 0.038; 
95 % CI 0.5192–0.8058; Fig. 4a), 0.704 (P = 0.008; 95 % CI 
0.5656–0.8418; Fig. 4b). The AUC for MIP-1β expressions 
in LGDH and LKYD was 0.612 and showed no significant 
difference (P = 0.16; 95 % CI 0.4574–0.7662; Fig. 4c).
Fig. 2 Classification of LGDH, LKYD, and HC groups by cytokines. a Plots representing the models discriminating the LGDH, LKYD, and HC groups. 
The metric multidimensional scaling (MDS) represents the proximity matrices of the RF models, which demonstrate the relationships among the 
three cohorts. The two axes represent the first and second MDS axes. Red dots LGDH patients; blue dots LKYD patients; green dots HCs. b Relative 
importance of the cytokines in the overall classification. The vertical axes represent the arrangement of individual cytokines according to their 
importance. The horizontal axes represent the average decrease in classification accuracy as the Gini scores. The important cytokines were associ‑
ated with a greater decrease in classification accuracy.
Fig. 3 Serum concentrations of candidate cytokines in CHB patients with LGDH or LKYD and in HCs. a–c Serum levels of IL‑17 (a), MIP‑1α (b), and 
MIP‑1β (c). LGDH patients, n = 30; LKYD patients, n = 30; HCs, n = 18. Data were analyzed by the Mann–Whitney U test.
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Furthermore, we applied a stepwise logistic regres-
sion model to combine the three cytokines for distin-
guishing between LGDH and LKYD. The logistic model 
(P = LKYD) = 61.50 − 0.402 × IL-17 + 0.336 × MIP-1α 
+ 0.008 × MIP-1β was used to construct the ROC curve. 
The diagnostic performance for the logistic panel was 
evaluated by ROC analysis. The AUC for the panel was 
0.827 (P < 0.001; 95 % CI 0.7256–0.9277; Fig. 4d).
Functional pathway analysis of significant cytokines 
in LGDH and LKYD
Cytokine-related signaling pathways were identified by 
DAVID. Sixteen enriched cytokines differed significantly 
between LGDH patients and HCs and nine cytokines 
differed significantly between LKYD patients and HCs. 
These significant cytokines were then analyzed for fur-
ther understanding of their biological relevance in LGDH 
and LKYD. Seven pathways in LGDH were significant 
at P < 0.05 (Table 3). The pathway of cytokine–cytokine 
receptor interaction showed the most significant P val-
ues in both the LGDH and LKYD groups, suggesting 
the strongest association with the input proteins after 
considering random chance. Toll-like receptor signaling 
pathway, intestinal immune network for IgA production, 
NOD-like receptor signaling pathway, and Jak-STAT 
signaling pathway were only enriched in the LGDH 
group, while the pathways of cytokine–cytokine receptor 
interaction, cytosolic DNA-sensing, and chemokine sign-
aling overlapped in the two groups.
Discussion
CM zhengs such as LGDH (excess zheng) and LKYD 
(deficiency zheng) reflect the two kinds of traditional CM 
syndromes underlying imbalances in the body. In CM, 
LGDH is recognized as dampness-heat accumulation in 
the liver and gallbladder resulting in impaired bile flow 
and downward pouring of dampness-heat, while LKYD 
is a pathological change in which insufficient yin fluid 
of the liver and kidney fails to nourish the related body 
constituents and organs, and gives rise to deficiency-
fire symptoms. The biological validity of these zhengs is 
still unclear, and biological indicators for distinguish-
ing LGDH from LKYD in CHB are also lacking [18]. In 
chronic viral hepatitis, cytokines modulate a number of 
critical biological processes, including angiogenesis, neo-
plastic growth, myofibroblast activation, and responses 
to viral infections [19, 20], and the cytokine activities lead 
to the development of fibrosis and cirrhosis [21].
Fig. 4 ROC curves for LGDH and LKYD differentiation in CHB. ROC curves were generated by cytokine expression data in CHB patients with LGDH 
(n = 30) and LKYD (n = 30). a–c The AUC values for IL‑17, MIP‑1α, and MIP‑1β were 0.663, 0.704, and 0.612, respectively. d The AUC value for a logis‑
tic panel with the combination of IL‑17, MIP‑1α, and MIP‑1β was 0.827.
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The changes in cytokines in chronic liver disease may 
be involved in zheng differentiation. This study is the 
first to stratify LGDH and LKYD in CHB using cytokine 
profiling technology. The results showed that the clini-
cal parameters can easily distinguish CHB patients from 
HCs, but could not differentiate between the zhengs 
(Table  1). After profiling of cytokines, we found nine 
cytokines that were differentially expressed between 
LGDH and LKYD. Sixteen cytokines were differentially 
expressed for multiple comparisons among the LGDH, 
LKYD, and HC groups (Table 2).
A multivariate analysis is required to understand the 
complex relationships between cytokines, and to pre-
dict which cytokines can allow discrimination of sample 
populations. Moreover, we used the RF method to search 
for potential biomarkers that can distinguish LGDH from 
LKYD. RF has excellent performance in classification 
tasks, and has been used in biomarker searches in high-
throughput technologies [22]. In this study, there were 
large Gini scores for IL-17, MIP-1α, and MIP-1β (Fig. 2) 
for LGDH and LKYD differentiation.
Furthermore, the candidate cytokines of IL-17, 
MIP-1α, and MIP-1β among the LGDH, LKYD, and 
HC groups were verified by ELISA-based immunoassay 
(Fig. 3). In CHB, the differentiation of Th17 cells was pro-
moted by inflammation in liver mesenchymal cells [23]. 
IL-17 is produced by Th17 cells, and plays a potential role 
in the amplification of intestinal inflammation stimulat-
ing endothelial cells, myofibroblasts, and epithelial cells. 
Besides, IL-17 was highly expressed in organ fibrosis [24]. 
In our study, IL-17 was elevated in the LKYD group com-
pared with the LGDH group, which was consistent with 
the development of chronic liver diseases. MIP-1α and 
MIP-1β expressions were found in the vascular endothe-
lium of the portal tracts in the normal and HBV-infected 
liver [25]. MIP-1α and MIP-1β led to increased prolifera-
tion and migration of hepatic stellate cells and mediated 
experimental liver fibrosis [26]. In our study, MIP-1α 
and MIP-1β were decreased in the LKYD group com-
pared with the LGDH group. The possible reason is that 
MIP-1α and MIP-1β may have chemoattracted differ-
ent leukocyte populations toward the inflammatory tis-
sue after continual infection. Therefore, the MIP-1α and 
MIP-1β levels were decreased in the peripheral blood. 
LGDH was often observed in the early phase with obvi-
ous inflammation in CHB. With the development of 
CHB, patients show some deficiency syndromes such 
as LKYD or mingled excess and deficiency syndromes 
instead of excess syndromes. The changes in CM zhengs 
usually follow the development of inflammation in CHB 
[27].
A ROC curve analysis was conducted to differenti-
ate LGDH and LKYD and observe the sensitivity and 
specificity of IL-17, MIP-1α, and MIP-1β. AUCs of IL-17 
and MIP-1α were significantly different from the null-
hypothesis, true area = 0.5 (meaning no discrimination). 
However, the AUC of MIP-1β was 0.612 and showed 
weak discrimination ability (P  =  0.16) (Fig.  4a–c). A 
larger sample size for validation of MIP-1β was required 
in the future. The logistic panel with the combination of 
the three cytokines from the multivariate logistic regres-
sion model demonstrated high accuracy in distinguish-
ing between LGDH and LKYD (Fig.  4d). Thus, multiple 
cytokines should be considered in zheng differentiation.
The differentially expressed cytokines were then ana-
lyzed for further understanding of their biological sig-
nificance in LGDH and LKYD. The functional pathway 
analysis indicated three pathways that overlapped in 
LGDH and LKYD. All three signaling pathways enriched 
in LKYD are also enriched in LGDH, which actually con-
tained markedly greater enrichment of Toll-like receptor 
signaling pathway, intestinal immune network for IgA 
production, NOD-like receptor signaling pathway, and 
Jak-STAT signaling pathway. Toll-like receptor signaling 
Table 3 Enriched signaling pathways in LGDH and LKYD
Zhengs Signaling pathways −log P value Cytokines
LGDH Cytokine‑cytokine receptor interaction 9.41 LIF, IL‑4, IL‑8, IL‑18, IL‑1β, IL‑15, MIP‑1α, CTACK, IP‑10
Cytosolic DNA‑sensing pathway 4.02 IL‑18, IL‑1β, MIP‑1α, IP‑10
Toll‑like receptor signaling pathway 3.23 IL‑8, IL‑1β, MIP‑1α, IP‑10
Intestinal immune network for IgA production 2.50 IL‑4, IL‑15, CTACK
Chemokine signaling pathway 2.46 IL‑8, MIP‑1α, CTACK, IP‑10
NOD‑like receptor signaling pathway 2.30 IL‑8, IL‑18, IL‑1β
Jak‑STAT signaling pathway 1.54 LIF, IL‑4, IL‑15
LKYD Cytokine‑cytokine receptor interaction 2.58 IL‑18, CTACK, IP‑10
Cytosolic DNA‑sensing pathway 1.67 IL‑18, IP‑10
Chemokine signaling pathway 1.14 CTACK, IP‑10
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pathway and JAK-STAT signaling pathway activations 
are frequently found in the initial responses to inflam-
mation. They induce the expressions of immune and pro-
inflammatory genes [28, 29]. This was consistent with the 
phenomenon that LGDH is usually observed in the ini-
tial stage of CHB and indicates the possibility that LGDH 
is a zheng that develops from LKYD. Toll-like recep-
tors and NOD-like receptors acted as key mediators for 
chronic liver injury [30]. They were found to be essential 
for the recognition of invading pathogens and served as 
important links between innate and adaptive immunity 
[31, 32]. The activation of JAK/STAT signaling in the 
liver was associated with increased hepatocyte prolif-
eration in response to stimulation by growth factors or 
partial hepatectomy [33]. Many tested proteins in these 
pathways were significantly represented in the setting of 
LKYD compared with LGDH, suggesting the different 
pathological states of these zhengs. With the activation 
of these particular enriched pathways, the zhengs may 
evolve from LGDH to LKYD.
All of the above results suggest that LKYD might serve 
for zheng-based treatment according to CM, i.e., “treat-
ing excess syndrome by purgation and treating deficiency 
syndrome by replenishment”. The successful prediction 
and selection of biological indicators contribute to the 
scientific interpretation of CM zhengs. In future studies, 
larger sample sizes and other zheng types of CHB should 
be employed. Because the cytokine regulation networks 
are complicated and remain unclear in HBV-derived 
chronic diseases, more cytokines should be tested and 
the overall mechanism is subject to further evaluation.
Conclusions
There were characteristic cytokine profiles in LGDH 
and LKYD with different inflammatory and immune 
responses. IL-17, MIP-1α, and MIP-1β might be involved 
in the differentiation of LGDH and LKYD in CHB.
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